Literature DB >> 15939094

Ventricular tachycardia in Chagas' disease: a comparison of clinical, angiographic, electrophysiologic and myocardial perfusion disturbances between patients presenting with either sustained or nonsustained forms.

Alvaro Valentim Lima Sarabanda1, Eduardo Sosa, Marcus Vinícius Simões, Geraldo Luís Figueiredo, Antônio Osvaldo Pintya, José Antônio Marin-Neto.   

Abstract

UNLABELLED: Ventricular tachycardia (VT) is common among patients with Chagas' heart disease but the ultimate mechanisms responsible for its sustained and nonsustained forms are not understood. This study aimed at determining which factors differentiate between patients with sustained (S-VT) and nonsustained VT (NS-VT). Fifty-six consecutive chagasic patients with VT were prospectively selected: 28 patients with spontaneous S-VT and 28 patients with NS-VT. The patients underwent clinical, angiographic, electrophysiologic and myocardial perfusion examination. Syncope episodes (S-VT: 43% versus NS-VT: 11%, p = 0.007) and induction of S-VT by programmed ventricular stimulation (S-VT: 89% versus NS-VT: 7%, p = 0.001) were significantly more frequent in S-VT patients. Evidence of a scar-related reentry was observed in all 24 S-VT patients who underwent endocardial mapping for attempted radiofrequency ablation of 33 VTs. Overall, 29 VTs arose from the LV (88%) and 4 VTs arose from the RV (12%). Among these, 27 VTs (82%) were related to LV inferolateral scar, 2 VTs (6%) were related to LV apical scar, and 4 VTs (12%) were related to RV scars. A significantly higher prevalence of wall motion abnormalities (S-VT: 82% versus NS-VT: 46%, p = 0.005) and myocardial perfusion defects (basal segments, S-VT: 95.5% versus NS-VT: 44%, p = 0.001) was documented within the LV inferior and/or posterolateral regions in S-VT patients compared to NS-VT. IN
CONCLUSION: (a) VT may arise from various regions in both ventricles, but LV inferolateral scar is the main source of S-VT reentrant circuits; (b) there is good topographic correlation between myocardial perfusion, wall motion abnormalities and areas that originate S-VT; (c) although to a lesser extent, wall motion and perfusion defects also occur in a relevant proportion of chagasics with NS-VT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939094     DOI: 10.1016/j.ijcard.2004.03.087

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  12 in total

Review 1.  The vasculature in chagas disease.

Authors:  Cibele M Prado; Linda A Jelicks; Louis M Weiss; Stephen M Factor; Herbert B Tanowitz; Marcos A Rossi
Journal:  Adv Parasitol       Date:  2011       Impact factor: 3.870

Review 2.  Epicardial interventions in electrophysiology.

Authors:  Noel G Boyle; Kalyanam Shivkumar
Journal:  Circulation       Date:  2012-10-02       Impact factor: 29.690

Review 3.  Diagnosis and Management of Chagas Cardiomyopathy in the United States.

Authors:  Lillian Benck; Evan Kransdorf; Jignesh Patel
Journal:  Curr Cardiol Rep       Date:  2018-10-11       Impact factor: 2.931

4.  The severity of ventricular arrhythmia correlates with the extent of myocardial sympathetic denervation, but not with myocardial fibrosis extent in chronic Chagas cardiomyopathy : Chagas disease, denervation and arrhythmia.

Authors:  Leonardo Pippa Gadioli; Carlos Henrique Miranda; Antonio Osvaldo Pintya; Alexandre Baldini de Figueiredo; André Schmidt; Benedito Carlos Maciel; José Antonio Marin-Neto; Marcus Vinicius Simões
Journal:  J Nucl Cardiol       Date:  2016-07-05       Impact factor: 5.952

Review 5.  Management of Cardiovascular Disease in Patients With COVID-19 and Chronic Chagas Disease: Implications to Prevent a Scourge Still Larger.

Authors:  Reinaldo Bulgarelli Bestetti; Edimar Alcides Bocchi; Renato Bestetti; Victor Sarli Issa; Rosemary Aparecida Furlan-Daniel; Marcelo Arruda Nakazone
Journal:  Front Med (Lausanne)       Date:  2022-06-29

Review 6.  Coronary microvascular disease in chronic Chagas cardiomyopathy including an overview on history, pathology, and other proposed pathogenic mechanisms.

Authors:  Marcos A Rossi; Herbert B Tanowitz; Lygia M Malvestio; Mara R Celes; Erica C Campos; Valdecir Blefari; Cibele M Prado
Journal:  PLoS Negl Trop Dis       Date:  2010-08-31

Review 7.  Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy.

Authors:  Claudio A Muratore; Adrian Baranchuk
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

8.  Bundle branch reentry: A novel mechanism for sustained ventricular tachycardia in Chagas heart disease.

Authors:  Alvaro V Sarabanda; Wagner L Gali; Gustavo G Gomes
Journal:  HeartRhythm Case Rep       Date:  2018-04-06

9.  Lower Prevalence and Severity of Coronary Atherosclerosis in Chronic Chagas' Disease by Coronary Computed Tomography Angiography.

Authors:  Savio Cardoso; Clerio Francisco de Azevedo Filho; Fábio Fernandes; Barbara Ianni; Jorge Andion Torreão; Mateus Diniz Marques; Luiz Francisco Rodrigues de Ávila; Raul Santos Filho; Charles Mady; Roberto Kalil-Filho; José Antônio Franchine Ramires; Marcio Sommer Bittencourt; Carlos E Rochitte
Journal:  Arq Bras Cardiol       Date:  2020-12       Impact factor: 2.000

10.  Epicardial ablation for ventricular tachycardia in chronic Chagas heart disease.

Authors:  Mauricio Scanavacca
Journal:  Arq Bras Cardiol       Date:  2014-06       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.